Table 1 Overview of the stage III NSCLC patient cohorts used for this study.

From: Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC

Name

RCT1*

RCT2

RCT3

S1*

S2

Center

Maastro Clinic (LUNG110,11,12)

Maastro Clinic (LUNG4)

Kantonsspital Aarau

Swiss multi-centric trial (SAKK 16/0013)

University Hospital Zurich

Patients

107

95

37

135

55

Treatment

RCT

RCT

RCT

RCT followed by surgery

RCT followed by surgery

OS events at 2 years

69.2%

50.5%

56.8%

37.8%

21.9%

Imaging

Single-institution

Single-institution

Single-institution

Multi-centric

Single-institution

In-plane resolution (mm)

0.98 (0)

0.98 (0)

0.98 (0)

0.98 (0.19)

1.04 (0.12)

Slice thickness (mm)

3.00 (0)

2.98 (0.15)

2.84 (1.04)

3.17 (1.18)

3.05 (0.45)

Number of CT reconstruction methods

8

6

2

16

6

Primary tumor volume (ml)

79.24 (94.4)

95.38 (102.12)

129.19 (124.60)

49.82 (56.81)

76.27 (99.44)

TNM edition

7

7

6

6

6

  1. Cohorts marked with an asterisk were used to create the decreased survival areas. These cohorts are referred to as exploratory cohorts and the remaining cohorts as independent cohorts. Patients of the independent cohorts were used to extract the smallest distance to decreased survival areas as a potential prognostic factor. Values are reported with mean (standard deviation).
Back to article page